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Abstract 
Human neurodegenerative tauopathies exhibit pathological tau aggregates in the brain along 
with diverse clinical features including cognitive and motor dysfunction. Post-translational 
modifications including phosphorylation, ubiquitination and truncation, are characteristic 
features of tau present in the brain in human tauopathy. We have previously reported an N-
terminally truncated form of tau in human brain that is associated with the development of 
tauopathy and is highly phosphorylated. We have generated a new mouse model of tauopathy 
in which this human brain-derived, 35 kDa tau fragment (Tau35) is expressed in the absence 
of any mutation and under the control of the human tau promoter. Most existing mouse 
models of tauopathy, overexpress mutant tau at levels that do not occur in human 
neurodegenerative disease, whereas Tau35 transgene expression is equivalent to less than 
10% of that of endogenous mouse tau. Tau35 mice recapitulate key features of human 
tauopathies, including aggregated and abnormally phosphorylated tau, progressive cognitive 
and motor deficits, autophagic/lysosomal dysfunction, loss of synaptic protein, and reduced 
life-span. Importantly, we found that sodium 4-phenylbutyrate (Buphenyl®), a drug used to 
treat urea cycle disorders and currently in clinical trials for a range of neurodegenerative 
diseases, reverses the observed abnormalities in tau and autophagy, behavioral deficits, and 
loss of synapsin-1 in Tau35 mice. Our results show for the first time that, unlike other tau 
transgenic mouse models, minimal expression of a human disease-associated tau fragment in 
Tau35 mice causes a profound and progressive tauopathy and cognitive changes, which are 
rescued by pharmacological intervention using a clinically approved drug. These novel Tau35 
mice therefore represent are a highly disease-relevant animal model in which to investigate 
molecular mechanisms and to develop novel treatments for human tauopathies. 
Keywords: Tau; tauopathies; progressive supranuclear palsy; 4-phenylbutyrate; lysosomal 
degradation 
 
Abbreviations: ANOVA = analysis of variance; bp = base-pair; CBD = corticobasal 
degeneration; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; GFAP = glial fibrillary 
acidic protein; GSK = glycogen synthase kinase-3; HA = haemagglutinin; Ig = 
immunoglobulin; KI = kyphotic index; LC3 = microtubule-associated protein 1-light chain 3; 
PBA = sodium 4-phenylbutyrate; PBS = phosphate-buffered saline; PFA = 
paraformaldehyde; PSP = progressive supranuclear palsy; RT = reverse transcription; TBS = 
Tris-buffered saline; WT = wild-type 
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Introduction 
Tauopathies are characterised by progressive cognitive and/or motor dysfunction, together 
with highly phosphorylated aggregates of the microtubule-associated protein tau in brain and 
peripheral nerve. Whilst Alzheimer’s disease is the most prevalent tauopathy, this group of 
disorders also includes progressive supranuclear palsy (PSP), corticobasal degeneration 
(CBD), Pick’s disease, and frontotemporal lobar degeneration with tau pathology (Lee et al., 
2001; Goedert and Spillantini, 2011). Although tau mutations are responsible for some 
tauopathies, the vast majority are sporadic and of unknown cause. Various forms of cleaved 
tau initiate tau aggregation, suggesting that this process may be critical for tauopathy 
pathogenesis (Wischik et al., 1988; Chung et al., 2001; Arai et al., 2004; Zilka et al., 2006; 
Zhang et al., 2014; Melis et al., 2015). However, the extent to which cleaved tau is involved 
in the development and progression of disease is unclear. 
 
We previously identified a highly phosphorylated C-terminal tau fragment in the brain of 
people affected by PSP, a common human tauopathy (Wray et al., 2008). To evaluate the 
pathological role of truncated tau, we generated a new transgenic mouse line (Tau35 mice) 
expressing this disease-associated tau fragment under the control of the human tau promoter. 
Existing rodent models of human tauopathy invariably involve overexpression of mutant or 
wild-type (WT) tau under the control of a variety of different promoters (Denk and Wade-
Martins, 2009; Zilka et al., 2009; Noble et al., 2010). These lines may exhibit substantial 
over-expression artefacts since increased tau concentration is detrimental to neuronal function 
(Ebneth et al., 1998). In contrast, transgene expression in Tau35 mice is only approximately 
5% of the total amount of tau, and thus non-physiological functions of over-expressed tau are 
avoided. Moreover, 35 kDa tau fragments are preferentially detected in human tauopathies in 
which four repeat forms of tau are over-represented, the most common tau isoform imbalance 
observed in the tauopathies (Goedert and Spillantini, 2011). Hence Tau35 mice may provide 
a model of disorders such as PSP and CBD, for which no mammalian models expressing WT 
tau currently exist. Nevertheless, the commonalities in tau-associated neurodegeneration 
between the different tauopathies suggest that Tau35 mice provide a human disease-relevant 
model with which to further our understanding of the molecular mechanisms underlying 
related disorders, such as Alzheimer’s disease. Importantly, Tau35 mice represent a 
pathophysiologically relevant mouse model in which to test new, potentially disease-
modifying, therapies. 
Page 3 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
4 
 
 
Herein we show that minimal expression of an N-terminally truncated tau fragment in Tau35 
mice leads to the development and progression of a human tauopathy-like disease phenotype, 
including altered tau processing and neuropathology, deficits in cognitive and motor function, 
muscle degeneration and impaired proteostasis. The disease course was modified upon 
treatment of Tau35 mice with sodium 4-phenylbutyrate (PBA, Buphenyl®), a drug currently 
in clinical use for the treatment of a variety of conditions, including neurodegenerative 
proteinopathies (Iannitti and Palmieri, 2011). Our findings describe a new, tractable animal 
model of tauopathy in which to (1) elucidate mechanisms underlying the development and 
progression of disease and (2) identify novel targets for the development of tau-based 
therapeutics. 
 
Materials and methods 
Preparation of insoluble fractions of human brain 
Frozen human cortex from PSP and control brain was obtained from the London 
Neurodegenerative Diseases Brain Bank (King's College London). Grey matter was 
homogenised (4ml/g tissue) in ice-cold MES buffer (100 mM 2-   [N- morpholino]ethane 
sulfonic acid, 0.5 mM MgCl2, 1 mM ethylene glycol tetraacetic acid, 1 M NaCl, Complete 
protease inhibitor [Roche], pH 6.5) and the homogenate was centrifuged at 3,000 g(av) for 10 
min at 4⁰C. The 3,000 g(av) pellets were analyzed on western blots, as described below. 
 
Generation of Tau35 transgenic mice 
Tau35 mice were generated by targeted knock-in of the Tau35 cDNA construct encoding the 
C-terminal half of wild-type human tau (amino acids 187-441) fused at the C-terminus to a 
hemagglutinin (HA) tag (Fig. 1A). The construct was expressed under the control of the 
human tau promoter and targeted to the Hprt locus using a “Quick Knock-in
TM
” targeting 
vector (genOway). The targeting vector was transfected into E14Tg2a embryonic stem cells, 
derived from 129/Ola mice. E14Tg2a cells lack 35kb of the Hprt gene, which is recovered by 
insertion of the transgenic cassette. Screening for successful homologous recombination was 
performed on Southern blots using probes hybridizing within the 5’ and 3’ homology arms of 
the targeting vector. Validated E14Tg2a cells were injected into C57BL6/J blastocysts. 
Heterozygous females were generated by mating the F1 generation of the male chimeras with 
C57BL/6 females. Heterozygous females were then crossed with wild-type C57BL/6J males 
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or with a transmitting chimera allowing the generation of hemizygous males and 
heterozygous females that were interbred to generate homozygous females. Mice were 
maintained on a background of 75% C57BL/6, 25% 129/Ola, bred and reared in-house, and 
weaned at 3 weeks of age. Mice had unlimited access to rodent chow (RM1 for all mice 
except breeders which received RM3, Special Diet Services) and water and were singly or 
group housed with a 12 hour light-dark cycle and constant temperature. Genotype-blinded 
behavioural assessments were conducted on male hemizygous transgenic and WT mice 
during the light phase. All animal experiments were carried out in accordance with the 
Animal (Scientiﬁc Procedures) Act 1986 (UK), and conformed to the ARRIVE guidelines on 
the ethical use of animals. 
 
Mouse genotyping by PCR 
Mouse ear notches were incubated in REDExtract-N-Amp (0.25 ml per sample, Sigma-
Aldrich PCR kit) at ambient temperature for 10 min, followed by the addition of neutralizing 
solution B (Sigma-Aldrich PCR kit). Samples were cycled using primers (Supplementary 
Table 1) and REDExtract-N-Amp PCR reaction mix. The following cycling conditions were 
used: one denaturing cycle at 94 ºC for 2 min, followed by 305 cycles of 94 ºC for 30 s, 55 ºC 
for 30 s, and 68 ºC for 5 min. PCR products were electrophoresed on 1.2% (w/v) agarose gels 
and visualised with ethidium bromide. 
 
Reverse transcription-PCR 
Total RNA was extracted from the hippocampus and associated cortex of Tau35 and WT 
mice (8 months old, 3 male hemizygous mice of each genotype) using TRI Reagent® 
(Sigma-Aldrich). cDNA was generated by reverse transcription (RT) (iScriptTM cDNA 
Synthesis Kit, Bio-Rad). To detect the endogenous mouse tau transcript, primers recognizing 
mouse tau exons 7 and 13 (Supplementary Table 1) were used to generate a 612 base-pair 
(bp) product by PCR. To identify the Tau35-HA transgene, a forward primer to tau exon 9 
and a reverse primer to HA were used to generate a 558 bp PCR product. Total tau mRNA 
was determined using tau primers to exons 9 and 13, yielding a 348 bp PCR product. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression was determined as 
described previously (Goetzl et al., 1999). To enable semi-quantitative analysis of the PCR 
products, DY682-labelled primers to tau exons 9 (forward) and 13 (reverse) and GAPDH 
(forward), were synthesised. The primer pairs of DY682-labelled exon 9 and unlabeled exon 
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13; unlabeled exon 7 and DY682-labelled exon13; and DY682-labelled GAPDH and 
unlabeled GAPDH, were used to measure total tau, endogenous mouse tau, and GAPDH 
mRNA, respectively. Prior to PCR, each DY682-labelled primer was pre-mixed with its 
unlabeled counterpart at a ratio of 1:4 for total tau, 1:6 for mouse tau and 1:9 for GAPDH. 
PCR products were separated by 1% (w/v) agarose gel electrophoresis and visualised using 
either ethidium bromide for unlabeled products, or the Odyssey infrared imaging system (Li-
Cor Biosciences) for DY682-labelled products. 
 
Mouse survival analysis 
Kaplan-Meier survival curves were for constructed for Tau35 and WT mice to analyze 
cumulative and median survival time using GraphPad Prism (n=10 for each genotype). 
 
Limb clasping 
Mice were suspended by the tail and assessed for hindlimb and forelimb clasping. Mice were 
scored as either clasping or not and the percentage of mice exhibiting clasping within each 
age group (n=40, aged 1-18 months) was determined. 
 
Kyphosis assessment 
To assess the degree of spinal curvature in the mice, a kyphotic index (KI) was determined 
using a method adapted from (Laws and Hoey, 2004). The distance from the last cervical 
vertebra to the caudal margin of the sixth lumbar vertebra (corresponding to the dip in the 
cervical region) was divided by the perpendicular distance to the most dorsal edge of the 
vertebra where the greatest curvature occurred. Mouse tissue was removed by dissolution in 
1% (w/v) KOH, 20% (v/v) glycerol and the spinal column was dissected out for imaging 
(n=8, aged 2-16 months).  
 
Rotarod 
Rotarod analysis was performed on an accelerating rotarod (UgoBasile7650, Linton 
Instruments). All mice received an initial acclimatization session for 2 min at 2 rpm, followed 
by a period of up to 500 s on the rotarod accelerating from 4 to 40 rpm over a period of 500 s, 
and the latency to fall was recorded (n=8, aged 2-16 months) (Hockly et al., 2003). 
 
 
Page 6 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
7 
 
Grip strength 
Mice were assessed for grip strength using a grip strength meter (Linton Instruments). 
Animals were lowered by their tail towards a metal grid and allowed to grasp the grid with 
either forelimbs only or all four limbs. Mice were then pulled steadily away from the 
apparatus with constant force and the maximum force was recorded. Grip strength was 
measured five times and the three highest values obtained from each animal were averaged 
(n=8, aged 2-16 months). 
 
Locomotor activity 
The locomotor activity of animals was assessed in a 60 cm diameter circular open field 
divided into outer, middle, and inner zones. Mice were placed in the outer part of the arena, 
facing the outer wall, and allowed to explore the open field freely for 30 min. Trials were 
videoed and analyzed (EthovisionXT7.1, Noldus), and the number of entries and the time 
spent in each zone were determined (n=8, aged 8 months). 
 
Olfactory habituation 
Mice were placed in a clean standard housing cage with bedding, and allowed to acclimatize 
for 24 h. After removal of bedding, odors were presented as follows: neutral (3 x water), non-
social (3 x banana), and social (3 x age-matched male mouse urine). Banana was diluted 
1/100 in water (Natural Products Co-op). Urine was diluted 1/250 in water. The time spent 
sniffing each odor was quantified for each trial, adapted from (n=8, aged 8 months) (Yang 
and Crawley, 2009). 
 
Morris water maze 
Spatial learning memory was assessed in mice at 4, 6, 8 and 12 months of age using the 
Morris water maze. Mice were trained to find a hidden platform for 5 consecutive days with 5 
min inter-trial intervals. A probe trial was conducted after the final day of hidden platform, 
during which the platform was removed. The time required to find the hidden platform during 
training, swim speed, total distance swam and the percentage time spent in each quadrant 
during the probe trial was determined using EthovisonXT (n=8, aged 2-16 months).  
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Treatment of mice with phenylbutyrate 
PBA was prepared by titrating equimolecular amounts of 4-phenylbutyric acid (Sigma-
Aldrich) with sodium hydroxide to pH 7.4 and filter sterilized. Groups of 8 Tau35 and WT 
mice (8.5 months) were treated with PBA (400mg/kg, i.p. daily) or vehicle (sterile water) for 
6 weeks, as described (Ricobaraza et al., 2009) (n=8 per treatment group).  
 
Preparation of mouse brain homogenate 
Mice were sacrificed by cervical dislocation and the brains were dissected into four regions 
(frontal region; hippocampus and associated cortex; amygdala; brain stem and cerebellum). 
Tissue was frozen immediately in liquid nitrogen and stored at -80⁰C until use. Brain tissue 
was disrupted in 1 ml ice-cold lysis buffer (10 mM Tris-HCl, pH 7.5, 75 mM NaCl, 0.5% 
(w/v) SDS, 20 mM sodium deoxycholate, 1% (v/v) Triton X-100, 2 mM sodium 
orthovanadate, 1.25 mM NaF, 1 mM sodium pyrophosphate, 10 mM ethylenediamine 
tetraacetic acid) using a Dounce homogenizer. 
 
Protein assay 
The protein concentrations of mouse brain preparations were determined using a 
bicinchoninic acid protein assay, according to the manufacturer (Thermo Scientific). 
 
Western blots of brain tissue 
Mouse and human brain proteins were electrophoresed on 10% (w/v) SDS-polyacrylamide 
gels. Insoluble pellets from human brain tissue were resuspended in SDS sample buffer and 
equivalent amounts were loaded onto gels. Separated proteins were transferred to 
nitrocellulose membranes, blocked in 5% (w/v) dried skimmed milk in phosphate-buffered 
saline (PBS) and incubated in primary antibodies (Supplementary Table 2), overnight at 4 C̊. 
After washing, membranes were incubated with the appropriate fluorophore-conjugated 
secondary antibody (Alexa Fluor ®680 goat anti-mouse immunoglobulin G [IgG] or IRDye 
TM 800 goat anti-rabbit IgG, Invitrogen; or horseradish peroxidase-labeled anti-rabbit IgG or 
anti-mouse IgG, GE Healthcare). Antigens were visualised using an Odyssey® infrared 
imaging system (Li-Cor Biosciences) or blots were developed using ECL Plus
TM
 (GE 
Healthcare) and quantitative analyses were performed using ImageJ software. 
 
 
Page 8 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
9 
 
Immunohistochemistry 
Tau35 mice and age-matched WT littermates, were sacrificed using terminal anesthesia, 
perfused with PBS followed by 4% (w/v) paraformaldehyde (PFA) in PBS. Brains were post-
fixed in 4% (w/v) PFA for 24 h, followed by 15% (w/v) sucrose for 5 h, and cryoprotection in 
30% (w/v) sucrose for 24 h. After freezing in isopentane, 30 µm coronal brain sections were 
sectioned using a cryostat and stored free-floating at -20°C in 30% (v/v) ethylene glycol, 15% 
(w/v) sucrose, and 0.05% (w/v) sodium azide in 50 mM Tris-buffered saline (TBS). Sections 
were washed in TBS and treated with 0.6% (v/v) hydrogen peroxide, prior to blocking in 2% 
(v/v) goat or horse serum in TBS, and incubating in primary antibody (Supplementary Table 
2) for 24 h at 4 °C. After washing, sections were incubated in the appropriate biotinylated 
secondary antibody (goat anti-rabbit IgG or horse anti-mouse IgG, Vector Laboratories) at 
ambient temperature, and developed using the ABC system (Vector Laboratories) with 
diaminobenzidine. Mounted sections were air-dried overnight and counterstained with 
hematoxylin. The number of tau inclusions within the hippocampus (CA1 and CA3) and 
cortex were counted to determine the extent of tau pathology. Muscle tissue was snap-frozen 
after dissection and 10µm cryostat sections were labeled using Harris’ hematoxylin and eosin 
counterstain (Vector Laboratories). The number of individual muscle fibers harboring 
internal nuclei was expressed as a percentage of the total muscle fibers. The minimal Feret’s 
diameter of 20-40 fibers from three animals of each genotype was calculated using ImageJ to 
determine the distribution of muscle fiber sizes. Images were captured using an EVOS® XL 
Imaging system or an Axioplan I microscope (Zeiss) using an Axiocam HRc camera (Zeiss). 
For HA immunolabeling, brains fixed with 4% (w/v) PFA were embedded in paraffin, and 7 
µm thick tissue sections cut with a microtome. Tissue sections were immunolabeled with the 
ABC method. 
 
Statistical analysis 
All statistical analyses were performed using SPSS software and graphs were prepared using 
GraphPad Prism. Normal distribution of data was tested using the Levine test for 
homogeneity of variance and the Kolmogorov-Smirnov test. One-way or two-way analysis of 
variance (ANOVA) was used to compare between groups. Kaplan Meier survival curves 
were analysed using GraphPad Prism. 
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Results 
35 kDa tau species are present in human tauopathy brain 
We previously reported that a C-terminal fragment of tau is associated with human four-
repeat tauopathies. To confirm these findings, we analyzed insoluble tau in pre-motor cortex 
from human PSP and control brain on western blots probed with antibody to tau (Fig. 1B). In 
agreement with our previous study, we found that PSP brain tissue contains 35kDa tau 
species that are absent from control human brain (Wray et al., 2008). 
 
Generation of Tau35 transgenic mice 
Mice expressing a C-terminal tau fragment were generated from Tau35 cDNA fused to a 
hemagglutinin (HA) tag to distinguish the transgene from endogenous mouse tau (Fig. 1A). 
The human tau promoter facilitated normal expression patterns of human tau and introduction 
of the construct into the mouse hypoxanthine phosphoribosyltransferase (Hprt) locus 
(Bronson et al., 1996) ensured single copy targeted integration, eliminating gene disruption 
around the insertion site and potential artefacts due to tau overexpression (Dawson et al., 
2007; Gotz et al., 2007). Male hemizygous Tau35 mice and WT littermate controls were used 
in this study. 
 
Expression of transgenic mRNA and protein in Tau35 mice 
To confirm Tau35-HA expression, RNA was extracted from mouse brains (male, 8 months) 
and RT-PCR was used to discriminate transgenically encoded mRNA (Supplementary Table 
1). Primers hybridizing to endogenous mouse tau exons 7 and 13 generated a 612 base-pair 
(bp) species in WT and Tau35 mice (Fig. 1C, left lanes). Primers hybridizing to tau exon 9 
and HA yielded a 558 bp band in Tau35, but not WT, mice (Fig. 1C, right lanes), confirming 
expression of HA-Tau35 in these animals. 
 
We next determined Tau35-HA transgene expression relative to endogenous mouse tau using 
two primer pairs, hybridizing to either endogenous mouse tau only (Supplementary Table 1, 
exons 7 and 13), or total tau (Supplementary Table 1, exons 9 and 13). DY682-labelled 
primers enabled semi-quantitative analysis of each PCR product (Fig. 1D), standardised to 
GAPDH. The total amount of tau mRNA was similar in WT and Tau35 mice, showing that 
Tau35 does not disturb expression of endogenous tau (Fig. 1D, P>0.05). The amount of 
mouse tau mRNA in Tau35 mice comprised 93% ± 2% of total tau expression (Fig. 1D, n=6 
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for each genotype). Hence, Tau35 transgene expression is estimated to comprise 
approximately 7% of total tau mRNA, similar to a previous report using the same promoter in 
tau mutant mice (Dawson et al., 2007). 
 
Translation of the transgenic tau fragment was verified in Tau35 mice by 
immunohistochemical labeling and on western blots using HA antibody (Fig. 1E). The 
distribution of HA labeling closely matches endogenous mouse tau expression in the Allen 
Developing Mouse Brain Atlas (©2014 Allen Institute for Brain Science. Available from: 
http://mouse.brain-map.org/ (Lein et al., 2007), including expression in the hippocampus, 
pontine grey, superior and inferior colliculus, and cerebellum. HA immunoreactivity was 
intense in cell bodies and dendrites of neurons, but was very weak or absent from axons in 
white matter tracts. The glial cells were not HA-positive. No HA labeling was apparent in 
WT mouse brain. Western blots of Tau35 and WT mouse brain fractions from the frontal 
region and hippocampus/associated cortex (HC) at 14 months showed a band of ~35kDa, the 
expected size of Tau35-HA, in Tau35 mice, which was absent from WT mice (Fig. 1E). 
 
Tau35 mice exhibit age-related limb clasping, kyphosis and reduced life span 
Aberrant clasping of forelimbs and/or hindlimbs on tail suspension is a common feature of 
tauopathy mouse models (Lewis et al., 2000; Dawson et al., 2007; Lalonde and Strazielle, 
2011). We found that Tau35 mice exhibit clasping by retraction or either hindlimbs or all four 
limbs examined with an incidence of 5% at 4 months, increasing dramatically to 25% at 5-6 
months, and with all Tau35 mice showing paresis by 18 months (Fig. 2A, n=40). Limb 
clasping was not observed in WT mice of the same age. These results demonstrate a 
progressive age-related loss of the normal limb extension reflex in Tau35 mice. 
 
Kyphosis has been reported in several murine models of neurodegenerative disease (Laws 
and Hoey, 2004; Lalonde et al., 2012; Wu et al., 2012) and abnormal spine curvature was 
apparent in Tau35 mice (Fig. 2B). We used a kyphotic index (KI) (Laws and Hoey, 2004) to 
quantify the degree of kyphosis in animals aged 4-14 months (Fig. 2B, n=8 mice for each 
genotype). The KI for WT mice was 4.4-4.6 at all ages examined, similar to previous reports 
(Laws et al., 2008; Vianello et al., 2014). At 4 months, Tau35 mice exhibited a KI of 4.5, 
which decreased to 3.4 at 8 months and continued to steadily decline, reaching 2.9 by 14 
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months. This dramatic reduction in KI demonstrates progressive, age-related kyphosis in 
Tau35 mice. 
 
The life spans of WT and Tau35 mice were determined and used to construct a Kaplan-Meier 
survival curve (Fig. 2C, n=10 for each genotype). Tau35 mice had a significantly reduced 
median survival of 717 days (P<0.05) compared to WT mice (788 days), showing that low-
level expression of Tau35 decreases life-span. Despite this reduced survival, there were no 
significant differences between the body masses of Tau35 and WT mice up to 18 months of 
age (Supplementary Fig. 1A). 
 
Tau35 mice exhibit neuromuscular and cognitive deficits 
Testing for motor co-ordination and learning ability on the accelerating rotarod showed that 
Tau35 mice have a reduced latency to fall, which decreased with age, indicating a progressive 
age-related defect in motor co-ordination (Fig. 2D, n=8). Defective rotarod performance by 
Tau35 mice could be compounded by reduced muscle strength and/or motor ability since the 
grip strength of WT mice measured in all four limbs progressively increased with age, whilst 
that of Tau35 mice remained constant up to 8 months and then deteriorated (Fig. 2E, n=8). 
Notably, the forelimb grip strength of Tau35 and WT mice was equivalent at all ages tested, 
showing that Tau35 expression primarily affected the hindlimbs in these mice (Fig. 2E, n=8).  
 
Multiple internalised nuclei and numerous degenerative/regenerative muscle fibers were 
apparent in the quadriceps and latissimus muscle of 8 and 16 month old Tau35 male mice 
(Fig. 2F). Fibrous endomysial connective tissue and occasional split fibers were noted in 
Tau35 mice in the absence of inflammatory infiltration. The distribution of fiber size was also 
altered in Tau35 mice aged 16 months, due to the presence of numerous small rounded fibers 
(Fig. 2F, n=3). Thus, expression of Tau35 results in substantial changes to muscle fibers that 
parallel the impairments in motor co-ordination and learning. 
 
Tau35 mice exhibit spatial learning and hippocampal dependent memory deficits. During 
cued visible platform (VP) training in the Morris water maze, the mean escape latency was 
similar for Tau35 and WT male mice aged 4-12 months (Fig. 3A, n=8), indicating no 
apparent visual or other physical deficiency affecting short term, cued learning. Using the 
hidden platform, the performance of Tau35 and WT mice did not differ significantly at 4 or 6 
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months (Fig. 3A). However, by 8 months, Tau35 mice showed a decreased latency to find the 
hidden platform and this impaired spatial learning and memory endured at 10 and 12 months 
(Fig. 3A). This deterioration in Tau35 mice was paralleled by an increased swim distance in 
locating the hidden platform at 8, 10 and 12 months (Fig. 3A). 
 
A probe trial conducted 24 hours after hidden platform training showed that hippocampal-
dependent memory as well as time spent in the target quadrant where the platform was 
previously present was impaired from 8 months in Tau35 mice (Fig. 3B, n=8). The swim 
speed of Tau35 and WT mice was comparable at all ages tested (Fig. 3B), excluding any 
potential confounding effects of hindlimb motor impairment on water maze performance. No 
differences were found in non-associative short-term memory olfaction or olfactory function 
or anxiety (Supplementary Fig. 1B,C) in Tau35 mice aged 8 months. Thus, the progressive 
reduction in the ability of Tau35 mice to find the hidden platform in the Morris water maze is 
due to cognitive impairment, rather than to defective motor function, or increased anxiety in 
these animals. 
 
Progressive increase in tau pathology in Tau35 mouse brain 
We examined hippocampal and cortical brain sections from Tau35 and WT male mice for the 
presence of abnormal tau. Labeling by antibody PHF1 (recognizing tau phosphorylated at 
Ser396/Ser404), was increased in the cytoplasm of Tau35 hippocampal neurons from 2 
months and dystrophic neurites were labeled at 8 months (Fig. 4). Western blots revealed an 
increased amount of tau phosphorylated at the PHF1 epitope, with no change in total tau, in 
Tau35 mice (Fig. 5A). Increased cytoplasmic staining was also evident in Tau35 
hippocampal neurons (8 months) labeled with antibodies recognizing abnormal tau 
conformations (TOC1 and MC1), tau phosphorylated at Ser202/Thr205 (AT8), and an 
antibody recognizing the N-terminus of tau (TP007), which is absent from transgenically 
expressed Tau35 (Fig. 4), indicating misfolding of endogenous mouse tau. By 14-16 months, 
tangle-like structures reactive for all of these tau antibodies were apparent in the 
hippocampus of Tau35 mice (Fig. 4, insets), similar to the pathology observed in tau over-
expressing mice (Lewis et al., 2000; Santacruz et al., 2005; Terwel et al., 2005; Schindowski 
et al., 2006; Yoshiyama et al., 2007). Using AT100 and pS422 antibodies, we found an 
appreciable amount of background labelling of 14 month old Tau35 brain, which was not 
present in WT mice of the same age. However, we were unable to detect distinct 
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immunopositive structures in Tau35 hippocampus with these two antibodies (data not 
shown). WT hippocampus up to 14-16 months did not show cytoplasmic or aggregated tau 
using the same tau antibodies (Fig. 4, n=3). A semi-quantitative analysis of tau 
immunoreactivity in Tau35 mice (2-16 months) showed increased tau pathology in CA1/CA3 
hippocampal regions and the cortex with aging (Supplementary Table 3). No changes in 
astrocyte morphology or the amount of glial fibrillary acidic protein (GFAP) were detected in 
Tau35 mice at 14 months (Supplementary Fig. 2A, B). Gallyas silver and thioflavine S 
staining were negative in both Tau35 and WT mice (data not shown). These results show that 
Tau35 mice exhibit a progressive tauopathy characterised by conformationally-altered, 
aggregated and phosphorylated tau, in the absence of astroglial activation. 
  
Increased tau phosphorylation and activation of GSK3β in Tau35 mice 
Western blots of HC brain homogenates from Tau35 and WT male mice aged 14 months, 
showed an approximate three-fold increase in PHF1 immunoreactivity relative to total tau 
(P<0.05) in the hippocampus and associated cortex, along with a slower migrating tau species 
in Tau35 mice (Fig 5A, arrowheads, n=6). Significant increases in tau phosphorylation were 
also found at epitopes corresponding to pT231 (Fig. 5B, TG3), pT181 (Fig. 5C, AT270), and 
S199/S202/T205 (Fig. 5D, Tau1, recognises dephosphorylated sites). The total amount of tau 
was similar in Tau35 and WT mice (Fig. 5A), which is in-line with the equivalent amounts of 
tau mRNA expression observed in these animals (Fig. 1D). 
 
Increased tau phosphorylation was paralleled by a reduction in inhibitory serine 9 
phosphorylation of the tau kinase, β (Fig. 6A, GSK3β, n=6), indicating increased GSK3β 
activity in Tau35 hippocampus (Hanger et al., 1992; Mandelkow et al., 1992; Lovestone et 
al., 1994; Leclerc et al., 2001; Bhat et al., 2003). No differences were observed in the 
amounts of either phosphorylated GSK3α or total GSK3α/β between Tau35 and WT mice 
(Fig. 6A). These results show a selective activation of GSK3β, but not GSK3α, in Tau35 
mice. 
 
Autophagy/lysosome-mediated degradation is impaired in Tau35 mice 
We next examined lysosome-mediated autophagic degradation by determining the amount of 
microtubule-associated protein 1-light chain 3 (LC3) present in male Tau35 mouse brain HC. 
During autophagy, cytosolic LC3-I is conjugated to phosphatidylethanolamine to form LC3-
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II, which is targeted to the autophagosome and is a marker of autophagosome accumulation. 
We found significant increases in both LC3-I and LC3-II in 14 month old Tau35 mice, 
compared to age-matched WT animals (Fig. 6B, LC3-I, p<0.001; LC3-II, p<0.05, n=6). 
These results suggest altered autophagic/lysosomal processes in Tau35 mice through 
increased production of LC3-I, enhanced conversion of LC3-I to LC3-II, and/or reduced 
lysosomal degradation of LC3-II (Mizushima and Yoshimori, 2007). 
 
We next examined the LC-3-II binding protein, p62/SQSTM1, which is degraded by 
autophagy and accumulates when autophagy is inhibited. Notably, p62 targets ubiquitinated 
and aggregated proteins, such as tau, to autophagosomes (Kuusisto et al., 2002; Komatsu et 
al., 2007; Bjorkoy et al., 2009; Richter-Landsberg and Leyk, 2013; Yan et al., 2013). 
Western blots of Tau35 mouse brain HC (14 months) revealed a 4.3-fold increase in the 
amount of p62 (Fig. 6C, n=6), supporting our finding of impaired autophagic/lysosomal 
function in Tau35 mice and suggesting a disruption in autophagic degradation. 
 
Soluble tau has been identified as a substrate for lysosomal proteases, such as cathepsin D, 
and inhibiting lysosomal function increases tau load (Kenessey et al., 1997; Bendiske and 
Bahr, 2003). We found a significant decrease of 54% in the amount of mature cathepsin D 
present in Tau35 mouse HC (14 months), whereas the amount of pro-cathepsin D was 
unchanged (Fig. 6D, p<0.05, n=6). These results indicate that lysosomal dysfunction may 
contribute to the defective autophagic degradation observed in Tau35 mice. 
 
Tubulin acetylation is a key component of autophagy, with acetylated microtubules being 
required for trafficking autophagosomal/lysosomal trafficking and LC3II degradation 
(Banreti et al., 2013). Acetylated microtubules are required for fusion of autophagosomes 
with lysosomes to form autolysosomes (Xie et al., 2010). Moreover, a reduction in α-tubulin 
acetylation in tangle-bearing neurons has been proposed as an early event in the development 
of tauopathy (Hempen and Brion, 1996; Cohen et al., 2011). Western blots of Tau35 mouse 
brain HC showed that acetylated α-tubulin was significantly reduced in Tau35 mice aged 14 
months, whilst the amount of α-tubulin was unchanged (Fig. 6E, n=6). Taken together, these 
findings suggest a significant impairment of molecular mechanisms related to autophagy and 
lysosomal-mediated degradation induced by Tau35 expression in mice.  
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Selective loss of synapsin-1 in Tau35 mouse brain 
To determine whether Tau35 mice exhibit altered synaptic integrity, we determined the 
amounts of the presynaptic markers, synapsin-1 and synaptophysin in Tau35 hippocampal 
tissue (14 months). We found a 65% reduction in the amount of synapsin-1 (Fig. 6F, n=6), 
but no change in the amount of synaptophysin (Fig. 6G), relative to tubulin, in Tau35 mice 
compared to WT mice. These results indicate a selective loss of releasable synaptic vesicles 
(Cesca et al., 2010), without affecting synaptophysin-regulated synaptic vesicle endocytosis 
(Kwon and Chapman, 2011) in Tau35 mice. 
 
Phenylbutyrate ameliorates the tauopathy-associated phenotype in Tau35 mice 
Sodium 4-phenylbutyrate (PBA) is a clinically approved, orally available, and blood-brain 
barrier penetrant drug which exhibits pleiotropic effects. PBA can act as a molecular 
chaperone, protecting against endoplasmic reticulum stress and the unfolded protein 
response, as well as acting as a an inhibitor of histone deacetylation (Wiley et al., 2010; 
Mimori et al., 2012; Cho et al., 2014). Notably, PBA prevents dendritic spine loss, improves 
cognitive function and reduces tau phosphorylation in mice overexpressing mutant amyloid 
precursor protein (Ricobaraza et al., 2009; Ricobaraza et al., 2012). Therefore, to determine 
whether the tauopathy-associated phenotype apparent in Tau35 mice is amenable to 
treatment, we administered PBA (400mg/kg, i.p., daily for 6 weeks) or vehicle, to groups of 
Tau35 and WT male mice at 8.5 months (Ricobaraza et al., 2009) and assessed them at 10 
months of age. Tau35 mice treated with PBA exhibited improved cognitive function in the 
Morris water maze (Fig. 7A, B, n=5), and increased grip strength (Fig. 7C, n=5). PBA also 
decreased tau phosphorylation at the PHF1 epitope by 52% in Tau35 mouse HC (Fig. 6D, 
n=5). Notably, whereas the elevations in LC3-I and LC3-II in Tau35 mouse HC were 
unaffected by PBA (Fig. 7E, n=5), the increased p62 was reduced by 57% compared to 
vehicle-treated animals (Fig. 7F, n=5). PBA treatment also resulted in a 37% increase in the 
amount of mature cathepsin D in Tau35 mouse HC (Fig. 7G, n=5), without affecting the 
amount of pro-cathepsin D (not shown). Furthermore, PBA induced a two-fold increase in 
acetylated α-tubulin in Tau35 mouse HC (Fig. 7H, n=5), without affecting the total amount of 
α-tubulin in either mouse line. The amount of synapsin-1 in Tau35 mouse brain HC was 
increased two-fold by PBA treatment (Fig. 7I, n=5), whereas synaptophysin remained 
unchanged (Fig. 7J, n=5). Importantly, PBA did not affect the mRNA expression of either 
Tau35 or endogenous mouse tau (Supplementary Fig. 3). Hematoxylin and eosin staining of 
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quadriceps muscle sections from Tau35 mice treated with PBA (Fig. 7K) showed that the 
number of internal nuclei in muscle fibres (arrows) was significantly decreased compared to 
vehicle-treated animals (P<0.05). Taken together, these results show that treatment with the 
clinically approved drug PBA, rescues the key phenotypical characteristics that emulate 
tauopathy in Tau35 mice. 
 
Discussion 
This is the first report of low-level expression of WT human tau in mice leading to the 
development of tauopathy. Targeted insertion of truncated WT human tau, comprising <10% 
of expressed endogenous mouse tau, causes progressive alterations in cognition and motor 
ability, together with neuropathological changes consistent with human disease. Low tau 
expression has been noted previously in mice harboring the same human tau promoter 
(Dawson et al., 2007) and the homologous rat tau promoter (Rosenmann et al., 2008) but 
importantly, in both of these animal models transgenically express mutant tau, which is 
present only infrequently in human tauopathy. Thus, Tau35 mice may better represent the 
spectrum of sporadic human tauopathies in which increased tau expression and tau mutations 
are not apparent (Hyman et al., 2005). 
 
Notably, progressive deficits in both motor ability and cognition are evident in Tau35 mice. 
The muscle changes observed in Tau35 mice are consistent with muscle denervation, 
possibly due to detrimental effects of truncated tau on (1) motoneuron function in the spinal 
cord, where we detected Tau35 expression (not shown), (2) tau transport into peripheral 
axons, and/or (3) autophagic/lysosomal degradative pathways. Early motor abnormality, 
followed by cognitive change, is reminiscent of human tauopathies such as PSP and CBD 
(Neary et al., 1998; Noble et al., 2010; Bruns and Josephs, 2013; Burrell et al., 2014; Litvan 
and Kong, 2014). Recently tau has been implicated in Huntington’s disease and in spinal 
muscular atrophy, suggesting additional roles for tau in muscle co-ordination and/or motor 
neuron degeneration in these disorders (Fernandez-Nogales et al., 2014; Miller et al., 2015). 
 
The brains of Tau35 mice display age-dependent inclusions comprised of the transgenically 
expressed human tau fragment, together with sequestered endogenous WT mouse tau that 
becomes highly phosphorylated and abnormally folded. However, even at terminal stages of 
disease, we did not observe high densities of tau inclusions in the brains of Tau35 mice, 
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indicating that the development of tangles per se may not be critical for continued cognitive 
and motor decline. Such a concept has been suggested previously in a transgenic mouse 
model in which mutant P301L tau is conditionally overexpressed (Santacruz et al., 2005). 
Suppression of mutant tau expression in these P301L tau mice enabled recovery of cognitive 
function and stabilization of neuronal numbers, whilst tangles continued to form (Santacruz 
et al., 2005). The lack of Sarkosyl-insoluble tau and the relatively paucity of tangle-like 
material in Tau35 mice, infer that the dysfunction induced by low level expression of N-
terminally truncated tau occurs in advance of significant accumulation of highly aggregated 
tau and is hence is more likely to result from oligomeric tau species, as has been suggested by 
others (de Calignon et al., 2010; Maeda et al., 2016).  It is conceivable therefore that an early 
neuronal deficit, without an overt neuropathological signature, occurs before the appearance 
of widespread fibrillar tau in Tau35 mice and in human tauopathies, and this may be 
responsible for cognitive dysfunction. 
 
Our finding of a selective increas  in GSK3β, but not GSK3α, activation in Tau35 mice 
suggests an important role for this tau kinase in disease pathogenesis, possibly related to its 
association with autophagic pathways (Inoue et al., 2012). Whilst we cannot exclude the 
possibility of altered activity of other tau kinases in Tau35 mice, the involvement of GSK3 in 
protein degradative mechanisms is significant. Inhibition of GSK3 activates the 
lysosomal/autophagic network by increasing the number of lysosomes, possibly mediated by 
effects on phosphorylation of transcription factor EB (TFEB), the master regulator of 
lysosome biogenesis (Parr et al., 2012). Although GSK3 has not been identified as a TFEB 
kinase, phosphorylation of TFEB affects its intracellular trafficking, with GSK3 inhibition 
leading to increased nuclear localization and induction of the autophagic-lysosomal system 
(Marchand et al., 2015). Increased GSK3 activity could therefore be proposed to lead to 
decreased nuclear TFEB, which would have an inhibitory effect on lysosomal functionality. 
Increased GSK3β activity can also suppress autophagy by impairing lysosomal acidification 
(Azoulay-Alfaguter et al., 2015). Importantly, a recent study has shown that TFEB promotes 
clearance of aggregated tau and enhances neuronal survival in rTg5410 transgenic mice 
overexpressing P301L tau through a mechanism involving lysosomal degradation (Polito et 
al., 2014). 
 
Furthermore, GSK3 phosphorylates p62 (Korolchuk et al., 2009), increases p62 and inhibits 
autophagic flux by reducing lysosomal acidification (Azoulay-Alfaguter et al., 2015). p62 
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targets aggregated proteins to autophagosomes for their subsequent removal and also 
accumulates if autophagy is defective (Komatsu et al., 2007; Richter-Landsberg and Leyk, 
2013; Yan et al., 2013). Therefore, our observation of an increase in p62, combined with 
augmented GSK3β activity, and elevations in both LC3-I and LC3-II, together suggest 
dysfunctional autophagy/lysosomal-mediated degradation as a potential neuropathological 
mechanism in Tau35 mice. 
 
The reduced amount of mature cathepsin D is also indicative of lysosomal dysfunction as a 
consequence of Tau35 expression. Accumulation of proteins targeted for degradation, 
together with impaired maturation of cathepsin D, would have a particularly adverse effect on 
neurons, which rely on autophagic degradation as a primary clearance system (Boland et al., 
2008). The observation of deficiencies in autophagy in human disease and in animal models 
of dementia give further support to the idea that this may be the mechanism that leads to loss 
of cognitive function in neurodegenerative tauopathies (Nixon, 2007; Nixon and Yang, 2011; 
Schaeffer et al., 2012; Vilchez et al., 2014; Ciechanover and Kwon, 2015). 
 
Decreased acetylated α-tubulin, a feature of tangle-bearing neurons (Hempen and Brion, 
1996), is a further indication of aberrant autophagy in Tau35 mice. Acetylated microtubules 
are critical for lysosomal fusion with autophagosomes and degradation of LC3-II (Xie et al., 
2010) as well as kinesin and dynein-dependent trafficking of lysosomes and/or 
autophagosomes (Reed et al., 2006). 
 
Very low expression of Tau35 results in significant tau pathology suggesting that the 
transgenically expressed tau fragment has deleterious effects on tau proteostasis. 
Sequestration of endogenous mouse tau into the intracellular inclusions, together with the 
appearance of misfolded tau and defective lysosomal degradation in Tau35 mice, indicate 
that this tau fragment, perhaps as a result of its abnormal conformation, induces disrupts  tau 
clearance pathways. One possibility is that Tau35 protein itself is transported to the lysosome 
for degradation where it could potentially interfere with the targeting of cellular proteins for 
clearance through the lysosome. Since increases in LC3-I, LC3-II and p62 are also observed 
in Tau35 hippocampus, this suggests that Tau35 could provoke a blockage in endolysosomal 
trafficking and thereby effectively overload physiological degradative pathways. Genetic 
studies have previously implicated autophagy and lysosomal degradation as major pathways 
that are disrupted in neurodegenerative disease (Yoon and Kim, 2016). An accumulation of 
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autophagic and lysosomal markers has been reported in human tauopathy brains, further 
suggesting that defects in these processes contribute to disease pathogenesis (Piras et al., 
2016). Activation of autophagy has also been shown to reduce the progression of tau 
pathology in P301S tau mice and has been suggested as a potential therapeutic approach for 
human tauopathy (Schaeffer et al., 2012). The similar lysosomal pathway deficits that are 
apparent in Tau35 mice suggest the possibility that this may be a primary mechanism through 
which Tau35 induces human tauopathy-like phenotypes in these mice. 
 
Importantly, we show here that tauopathy in Tau35 mice is rescued by PBA, a clinically 
approved drug, which has been tested in clinical trials for a variety of neurodegenerative 
diseases, including Huntington’s disease, motor neuron disease, cancer, and cystic fibrosis 
(Iannitti and Palmieri, 2011). PBA has been shown previously to improve cognition and to 
reduce tau phosphorylation in mice overexpressing mutant amyloid precursor protein 
(Ricobaraza et al., 2009). Notably, PBA reverses the substantial deficits in cognition and 
behaviour, as well as biochemical and muscle abnormalities, in Tau35 mice. This is 
significant for the treatment of human disease, which is diagnosed by the appearance of 
clinical symptoms only after development of substantial tau pathology, which invariably 
occurs late in the disease course. 
 
To our knowledge, this is the first report that very low amounts of a fragment of WT human 
tau in mice leads to behavioral, neuropathological and biochemical changes that closely 
recapitulate human disease. Since tauopathy in these mice can be reversed by PBA, this 
provides new opportunities to investigate disease mechanisms and to initiate potential new 
treatments for neurodegenerative tauopathies. 
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Figure legends  
 
Figure 1. Tau expression in human tauopathy and Tau35 mouse brain. (A) Construct 
used to generate Tau35 mice with the human tau promoter (phTau), upstream of the Tau35 
sequence with the hemagglutinin tag (HA). The hypoxanthine phosphoribosyltransferase 
promoter (pHprt) and exons 1-3 enabled targeted integration of the Tau35-HA transgene. The 
lower panel shows a schematic representation of the expressed Tau35-HA protein in 
comparison to full-length human tau (441 amino acids). The amino terminal domain of tau 
contains two inserts (N1, N2), followed by a central proline-rich domain and the microtubule 
(MT) binding domain, which comprises four repeats (R1-R4). Tau35 retains the majority of 
the proline-rich domain, four MT binding repeats and an intact C-terminus. The epitopes of 
the phospho-dependent (orange boxes), conformation-dependent (black boxes) and region-
specific (grey boxes) tau antibodies used in this study are indicated above full-length tau. (B) 
Western blot of insoluble fractions of control and progressive supranuclear palsy (PSP) brain 
reveals the 35 kDa tau species (*) in the pre-motor cortex of human PSP brain probed with 
TP70, the C-terminal tau antibody. (C) Reverse transcription (RT)-PCR to confirm Tau35 
expression. Primers recognizing mouse tau (exons 7 and 13) generate a 612 base-pair (bp) 
band, corresponding to endogenous mouse tau in wild-type (WT) and Tau35 mice. Primers 
recognizing tau exon 9 and HA generate a 558 bp band only in Tau35 mice. (D) RT-PCR of 
endogenous mouse and total tau in WT and Tau35 mice. PCR products amplified using 
primers for mouse tau (exons 7 and 13, 612 bp) or total tau (exons 9 and 13, 348 bp) in WT 
and Tau35 mice, standardised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Results are shown as mean ± s.e.m. (n=6 mice for each genotype). (E) Sagittal sections show 
widespread HA labeling in Tau35 mouse brain (upper panels, scale bar=2 mm). Higher 
magnifications of the hippocampal CA1 region show strongly HA-positive pyramidal 
neurons in Tau35 mice (lower panels, scale bar=200 µm). Western blots of frontal region and 
hippocampus/associated cortex (HC) show HA protein expression only in Tau35 mice. 
 
Figure 2. Progressive neuromuscular impairment and reduced survival of Tau35 mice. 
(A) Limb clasping is apparent in Tau35 mice from 2 months of age (image shows 8 months), 
with all Tau35 animals affected by 18 months (n=40 mice). Clasping is not observed in wild-
type (WT) mice at any age examined. (B) Spine curvature is apparent in Tau35 but not WT 
mice, at 14 months of age. A progressive reduction in the kyphotic index in Tau35 mice after 
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4 months of age indicates increasing spine curvature. Values shown are mean ± s.e.m., n=8 
mice for each genotype. (C) Kaplan-Meier survival plots reveal a median lifespan of 717 
days for Tau35 mice, compared to 788 days for WT mice (P<0.05, log-rank test, pairwise 
multiple comparison and Bonferroni correction), n=10 mice for each genotype. (D) Tau35 
mice have a significantly reduced latency to fall from an accelerating rotarod at all ages 
tested (4-16 months). Values shown are mean ± s.e.m., n=8 mice for each genotype. (E) The 
grip strength of Tau35 mice declines steadily with age. Values shown are mean ± s.e.m., n=8 
for each genotype. (F) Hematoxylin and eosin staining of quadriceps and latissimus muscle 
sections from WT and Tau35 mice at 8 and 16 months. Muscle fibres from Tau35 mice show 
internal nuclei at 8 and 16 months (arrows). Scale bar=60µm. Graphs show increased internal 
nuclei (8 and 16 months) and altered distribution of muscle fiber diameter (minimal Feret’s 
diameter, 16 months) in Tau35 mice. Values shown are mean ± s.e.m., n=3 mice for each 
genotype. *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 3. Tau35 mice exhibit reduced hippocampal-dependent spatial learning ability in 
the Morris water maze. (A) Visible platform (VP) training in the Morris water maze was 
followed by four days of hidden platform training. Escape latencies were tracked for 
independent cohorts of Tau35 and wild-type (WT) mice at 4, 6, 8, 10 and 12 months of age. 
At 8, 10 and 12 months of age, Tau35 mice exhibit longer escape latency on the fourth days 
of testing compared to WT mice. The distance swam by Tau35 mice searching for the hidden 
platform is significantly increased compared to WT mice at 8, 10 and 12 months of age. (B) 
During the probe trial (1 min), the percentage occupancy of the target quadrant is 
significantly reduced for Tau35 mice compared to WT mice at 8 months. Tau35 and WT 
mice exhibit equivalent swim speeds during the probe trial indicating no apparent impairment 
in swimming ability at the ages tested. Values shown in A and B are mean ± s.e.m., n=8 mice 
for each genotype. *P<0.05, **P<0.01, ***P<0.001.  
 
Figure 4.  Tau pathology in Tau35 mouse brain. CA1 hippocampal sections of Tau35 mice 
at 2, 8, and 14-16 months of age, and wild-type (WT) mice aged 16 months (right panels), 
labelled with tau antibodies, PHF1, TOC1, MC1, AT8 and TP007, and counterstained with 
hematoxylin. PHF1 revealed tau-positive labelling at 2 months. Tau-positive labelling of 
inclusions in Tau35 brain, including dystrophic neurites and neuropil threads, was apparent 
with antibodies PHF1, TOC1, MC1, AT8 and TP007 at 14-16 months (insets). PHF1 
revealed increased cytoplasmic labelling at 2 months and tau-containing inclusions from 8 
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months, which were more abundant at 14-16 months. Wild-type (WT) hippocampal sections 
showed no labelling of inclusions with these antibodies at 14-16 months of age (right panels). 
n=3 mice for each genotype, scale bar=200µm. 
 
Figure 5. Tau phosphorylation changes in Tau35 mouse hippocampus. Western blots of 
(A) PHF1, total tau, and β-actin, (B) TG3 and total tau, and (C) AT270 and total tau, reveal a 
significant increase in tau phosphorylation in Tau35 mice at each phosphoepitope, compared 
to wild-type (WT) mice, whereas the total amount of tau relative to actin is equivalent in both 
genotypes. (D) Western blots of Tau1 and total tau, show a reduction in tau phosphorylation 
in Tau35 mice.  Values shown are mean ± s.e.m., n=6 mice for each genotype. *P<0.05, 
***P<0.001. 
 
Figure 6. Biochemical changes in Tau35 mouse hippocampus. Western blots show (A) 
phosphorylated (inactive) glycogen synthase kinase-3β (pGSK3β) relative to total (T-) 
GSK3β, is significantly decreased in Tau35 mice, indicating increased GSK3β activity. The 
total amounts of GSK3α and GSK3β, and of pGSK3α, are unchanged in Tau35 mice. (B) 
Western blot shows the amounts of microtubule-associated protein 1-light chain 3 (LC3)-I 
and LC3-II, relative to actin, are increased in Tau35 mice. (C) p62 is significantly increased, 
relative to actin, in Tau35 mice. (D) Mature (active) cathepsin D is reduced in Tau35 mice, 
whilst the amount of pro-cathepsin D is unchanged. (E) Western blots show a small but 
significant decrease in acetylated α-tubulin in Tau35 mice. The total amount of tubulin 
relative to actin is equivalent in both genotypes. (F) The amount of synapsin-1 is reduced 
relative to tubulin, whereas synaptophysin is unchanged in Tau35 mice (G). Values shown 
are mean ± s.e.m., n=6 mice for each genotype. *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 7. Phenylbutyrate rescues disease-related changes in Tau35 mice. (A) Morris 
water maze (10 months) testing of 4-phenylbutyrate (PBA, squares, dotted lines) and vehicle-
treated (circles, solid lines) Tau35 (grey) and wild-type (WT, black) mice. (B) Tau35 mice 
treated with PBA show improved learning in the probe trial at 10 months of age. (C) Grip 
strength of Tau35 (10 months) is restored by PBA treatment. Values shown in A-C are mean 
± s.e.m., n=8 mice for each group. Western blots show that Tau35 mice treated with PBA 
have (D) reduced phosphorylated tau (PHF1), relative to total tau, whereas the amounts of 
microtubule-associated protein 1-light chain 3 (LC3)-I and LC3-II are unchanged, relative to 
actin (E). PBA significantly reduced p62 in Tau35 mice compared to vehicle-treated animals 
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(F). The amount of mature cathepsin D, but not pro-cathepsin D, is rescued by PBA treatment 
of Tau35 mice (G). Acetylated α-tubulin (H) and synapsin-1 (I) are both increased in Tau35 
mice following PBA treatment, whereas the amount of synaptophysin is unchanged (J). 
Values shown in D-J are mean ± s.e.m., n=5 mice for each group. (K) Hematoxylin and eosin 
staining of quadriceps muscle sections from Tau35 mice treated with vehicle (left) or PBA 
(right). Muscle fibres from vehicle-treated Tau35 mice show internal nuclei at 10 months 
(left, arrows). Scale bar=60µm.  Graph shows reduced internal nuclei in Tau35 mice treated 
with PBA. Values shown are mean ± s.e.m., n=3 mice for each group. *P<0.05, **P<0.01, 
***P<0.001. 
  
Page 25 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
26 
 
References  
Arai T, Ikeda K, Akiyama H, Nonaka T, Hasegawa M, Ishiguro K, et al. Identification of 
amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from 
corticobasal degeneration. Ann Neurol 2004; 55(1): 72-9. 
 
Azoulay-Alfaguter I, Elya R, Avrahami L, Katz A, Eldar-Finkelman H. Combined regulation 
of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to 
cancer cell growth. Oncogene 2015; 34(35): 4613-23. 
 
Banreti A, Sass M, Graba Y. The emerging role of acetylation in the regulation of autophagy. 
Autophagy 2013; 9(6): 819-29. 
 
Bendiske J, Bahr BA. Lysosomal activation is a compensatory response against protein 
accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer 
disease? J Neuropathol Exp Neurol 2003; 62(5): 451-63. 
 
Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al. Structural insights and 
biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 
2003; 278(46): 45937-45. 
 
Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T. Monitoring autophagic 
degradation of p62/SQSTM1. Methods Enzymol 2009; 452: 181-97. 
 
Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and 
autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's 
disease. J Neurosci 2008; 28(27): 6926-37. 
Page 26 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
27 
 
 
Bronson SK, Plaehn EG, Kluckman KD, Hagaman JR, Maeda N, Smithies O. Single-copy 
transgenic mice with chosen-site integration. Proc Natl Acad Sci U S A 1996; 93(17): 9067-
72. 
 
Bruns MB, Josephs KA. Neuropsychiatry of corticobasal degeneration and progressive 
supranuclear palsy. Int Rev Psychiatry 2013; 25(2): 197-209. 
 
Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive 
supranuclear palsy: a review. Mov Disord 2014; 29(5): 684-93. 
 
Cesca F, Baldelli P, Valtorta F, Benfenati F. The synapsins: key actors of synapse function 
and plasticity. Prog Neurobiol 2010; 91(4): 313-48. 
 
Cho JA, Zhang X, Miller GM, Lencer WI, Nery FC. 4-phenylbutyrate attenuates the ER 
stress response and cyclic AMP accumulation in DYT1 dystonia cell models. PLoS ONE 
2014; 9(11): e110086. 
 
Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG, et al. Proapoptotic effects of tau 
cleavage product generated by caspase-3. NeurobiolDis 2001; 8(1): 162-72. 
 
Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: 
therapeutic targets and strategies. Exp Mol Med 2015; 47: e147. 
 
Page 27 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
28 
 
Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation 
of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2011; 2: 
252. 
 
Dawson HN, Cantillana V, Chen L, Vitek MP. The tau N279K exon 10 splicing mutation 
recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy 
in a mouse model. J Neurosci 2007; 27(34): 9155-68. 
 
de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, et al. Caspase 
activation precedes and leads to tangles. Nature 2010; 464(7292): 1201-4. 
 
Denk F, Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol 
Aging 2009; 30(1): 1-13. 
 
Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. Overexpression 
of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and 
endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 1998; 143(3): 777-
94. 
 
Fernandez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller 
AJ, et al. Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 
2014; 20(8): 881-5. 
 
Goedert M, Spillantini MG. Pathogenesis of the tauopathies. J Mol Neurosci 2011; 45(3): 
425-31. 
Page 28 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
29 
 
 
Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, Kalli KR, et al. Distinctive expression 
and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled 
receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 1999; 59(20): 5370-5. 
 
Gotz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, et al. A decade of tau transgenic 
animal models and beyond. Brain Pathol 2007; 17(1): 91-103. 
 
Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 
induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical 
filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1992; 147(1): 58-62. 
 
Hempen B, Brion JP. Reduction of acetylated à-tubulin immunoreactivity in neurofibrillary 
tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55(9): 964-
72. 
 
Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, et al. Suberoylanilide 
hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model 
of Huntington's disease. Proc Natl Acad Sci U S A 2003; 100(4): 2041-6. 
 
Hyman BT, Augustinack JC, Ingelsson M. Transcriptional and conformational changes of the 
tau molecule in Alzheimer's disease. Biochim Biophys Acta 2005; 1739(2-3): 150-7. 
 
Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. 
Drugs R D 2011; 11(3): 227-49. 
Page 29 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
30 
 
 
Inoue K, Rispoli J, Kaphzan H, Klann E, Chen EI, Kim J, et al. Macroautophagy deficiency 
mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol 
Neurodegener 2012; 7: 48. 
 
Kenessey A, Nacharaju P, Ko LW, Yen SH. Degradation of tau by lysosomal enzyme 
cathepsin D: implication for Alzheimer neurofibrillary degeneration. J Neurochem 1997; 
69(5): 2026-38. 
 
Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, et al. Homeostatic levels of p62 
control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007; 
131(6): 1149-63. 
 
Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC. Autophagy inhibition 
compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009; 33(4): 
517-27. 
 
Kuusisto E, Salminen A, Alafuzoff I. Early accumulation of p62 in neurofibrillary tangles in 
Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 2002; 
28(3): 228-37. 
 
Kwon SE, Chapman ER. Synaptophysin regulates the kinetics of synaptic vesicle endocytosis 
in central neurons. Neuron 2011; 70(5): 847-54. 
 
Page 30 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
31 
 
Lalonde R, Fukuchi K, Strazielle C. Neurologic and motor dysfunctions in APP transgenic 
mice. Rev Neurosci 2012; 23(4): 363-79. 
 
Lalonde R, Strazielle C. Brain regions and genes affecting limb-clasping responses. Brain 
research reviews 2011; 67(1-2): 252-9. 
 
Laws N, Cornford-Nairn RA, Irwin N, Johnsen R, Fletcher S, Wilton SD, et al. Long-term 
administration of antisense oligonucleotides into the paraspinal muscles of mdx mice reduces 
kyphosis. J Appl Physiol (1985) 2008; 105(2): 662-8. 
 
Laws N, Hoey A. Progression of kyphosis in mdx mice. J Appl Physiol (1985) 2004; 97(5): 
1970-7. 
 
Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, et al. Indirubins inhibit 
glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal 
tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent 
kinase inhibitors? J Biol Chem 2001; 276(1): 251-60. 
 
Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 
2001; 24: 1121-59. 
 
Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, et al. Genome-wide atlas 
of gene expression in the adult mouse brain. Nature 2007; 445(7124): 168-76. Available 
from: http://mouse.brain-map.org/. 
 
Page 31 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
32 
 
Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. 
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing 
mutant (P301L) tau protein. NatGenet 2000; 25(4): 402-5. 
 
Litvan I, Kong M. Rate of decline in progressive supranuclear palsy. Mov Disord 2014; 
29(4): 463-8. 
 
Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, et al. 
Alzheimer's disease-like phosphorylation of the microtubule- associated protein tau by 
glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994; 4(12): 1077-86. 
 
Maeda S, Djukic B, Taneja P, Yu GQ, Lo I, Davis A, et al. Expression of A152T human tau 
causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep 2016. 
 
Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR, et al. 
Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein 
tau. FEBS Lett 1992; 314: 315-21. 
 
Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ. Glycogen 
synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human 
pancreatic cancer cells. J Biol Chem 2015; 290(9): 5592-605. 
 
Melis V, Zabke C, Stamer K, Magbagbeolu M, Schwab K, Marschall P, et al. Different 
pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes 
Page 32 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
33 
 
in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration. Cell 
Mol Life Sci 2015; 72(11): 2199-222. 
 
Miller N, Feng Z, Edens BM, Yang B, Shi H, Sze CC, et al. Non-aggregating tau 
phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in 
spinal muscular atrophy. J Neurosci 2015; 35(15): 6038-50. 
 
Mimori S, Okuma Y, Kaneko M, Kawada K, Hosoi T, Ozawa K, et al. Protective effects of 
4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress. 
Biol Pharm Bull 2012; 35(1): 84-90. 
 
Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3(6): 
542-5. 
 
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar 
degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51(6): 1546-54. 
 
Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 2007; 120(Pt 23): 
4081-91. 
 
Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease--locating the primary defect. 
Neurobiol Dis 2011; 43(1): 38-45. 
 
Noble W, Hanger DP, Gallo JM. Transgenic mouse models of tauopathy in drug discovery. 
CNS Neurol Disord Drug Targets 2010; 9(4): 403-28. 
Page 33 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
34 
 
 
Parr C, Carzaniga R, Gentleman SM, Van Leuven F, Walter J, Sastre M. Glycogen synthase 
kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the 
amyloid-beta precursor protein. Mol Cell Biol 2012; 32(21): 4410-8. 
 
Piras A, Collin L, Gruninger F, Graff C, Ronnback A. Autophagic and lysosomal defects in 
human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer 
disease, corticobasal degeneration and progressive supranuclear palsy. Acta neuropathologica 
communications 2016; 4(1): 22. 
 
Polito VA, Li H, Martini-Stoica H, Wang B, Yang L, Xu Y, et al. Selective clearance of 
aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. EMBO Mol Med 
2014; 6(9): 1142-60. 
 
Reed NA, Cai D, Blasius TL, Jih GT, Meyhofer E, Gaertig J, et al. Microtubule acetylation 
promotes kinesin-1 binding and transport. Curr Biol 2006; 16(21): 2166-72. 
 
Richter-Landsberg C, Leyk J. Inclusion body formation, macroautophagy, and the role of 
HDAC6 in neurodegeneration. Acta Neuropathol 2013; 126(6): 793-807. 
 
Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otano I, Garcia-Osta A. Phenylbutyrate 
rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer 
disease. Hippocampus 2012; 22(5): 1040-50. 
 
Page 34 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
35 
 
Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta 
A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's 
disease mouse model. Neuropsychopharmacology 2009; 34(7): 1721-32. 
 
Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, et al. A 
novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits 
tauopathy characteristics. Exp Neurol 2008; 212(1): 71-84. 
 
Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in 
a neurodegenerative mouse model improves memory function. Science 2005; 309(5733): 
476-81. 
 
Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of 
autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 2012; 
135(Pt 7): 2169-77. 
 
Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, et al. Alzheimer's 
disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a 
novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 2006; 169(2): 
599-616. 
 
Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van HC, Borghgraef P, et al. Changed 
conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, 
nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem 2005; 280(5): 3963-73. 
 
Page 35 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
36 
 
Vianello S, Bouyon S, Benoit E, Sebrie C, Boerio D, Herbin M, et al. Arginine butyrate per 
os protects mdx mice against cardiomyopathy, kyphosis and changes in axonal excitability. 
Neurobiol Dis 2014; 71: 325-33. 
 
Vilchez D, Saez I, Dillin A. The role of protein clearance mechanisms in organismal ageing 
and age-related diseases. Nat Commun 2014; 5: 5659. 
 
Wiley JC, Meabon JS, Frankowski H, Smith EA, Schecterson LC, Bothwell M, et al. 
Phenylbutyric acid rescues endoplasmic reticulum stress-induced suppression of APP 
proteolysis and prevents apoptosis in neuronal cells. PLoS ONE 2010; 5(2): e9135. 
 
Wischik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R, et al. Isolation 
of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. 
Proc Natl Acad Sci U S A 1988; 85: 4506-10. 
 
Wray S, Saxton M, Anderton B, Hanger D. Direct analysis of tau from PSP brain identifies 
new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four 
microtubule-binding repeats. J Neurochem 2008; 105(6): 2343-52. 
 
Wu LS, Cheng WC, Shen CK. Targeted depletion of TDP-43 expression in the spinal cord 
motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in 
mice. J Biol Chem 2012; 287(33): 27335-44. 
 
Xie R, Nguyen S, McKeehan WL, Liu L. Acetylated microtubules are required for fusion of 
autophagosomes with lysosomes. BMC Cell Biol 2010; 11: 89. 
Page 36 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
37 
 
 
Yan J, Seibenhener ML, Calderilla-Barbosa L, Diaz-Meco MT, Moscat J, Jiang J, et al. 
SQSTM1/p62 interacts with HDAC6 and regulates deacetylase activity. PLoS ONE 2013; 
8(9): e76016. 
 
Yang M, Crawley JN. Simple behavioral assessment of mouse olfaction. Curr Protoc 
Neurosci 2009; Chapter 8: Unit 8.24. 
 
Yoon SY, Kim DH. Alzheimer's disease genes and autophagy. Brain Res 2016. 
 
Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and 
microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 
53(3): 337-51. 
 
Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, et al. Cleavage of tau by 
asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat 
Med 2014; 20(11): 1254-62. 
 
Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, et al. Truncated tau from 
sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 
2006; 580(15): 3582-8. 
 
Zilka N, Korenova M, Novak M. Misfolded tau protein and disease modifying pathways in 
transgenic rodent models of human tauopathies. Acta Neuropathol 2009; 118(1): 71-86. 
 
 
Page 37 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
  
 
 
Figure 1. Tau expression in human tauopathy and Tau35 mouse brain  
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Figure 2. Progressive neuromuscular impairment and reduced survival of Tau35 mice  
297x420mm (300 x 300 DPI)  
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Figure 3. Tau35 mice exhibit reduced hippocampal-dependent spatial learning ability in the Morris water 
maze  
297x420mm (300 x 300 DPI)  
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Figure 4.  Tau pathology in Tau35 mouse brain  
297x420mm (300 x 300 DPI)  
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Figure 5. Tau phosphorylation changes in Tau35 mouse hippocampus  
297x420mm (300 x 300 DPI)  
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Figure 6. Biochemical changes in Tau35 mouse hippocampus  
297x420mm (300 x 300 DPI)  
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Figure 7. Phenylbutyrate rescues disease-related changes in Tau35 mice  
297x420mm (300 x 300 DPI)  
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Supplementary information 
 
Low expression of a human brain-associated tau fragment in mice induces 
tauopathy that is rescued by phenylbutyrate 
 
Bondulich et al 
 
  
Page 45 of 55
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 
2 
 
Supplementary Table 1: Primers used for PCR 
 
Primer Sequence Reference 
Tau exon 7-forward 5’-AGCCCTAAGACTCCTCCA-3’  (de Calignon 
et al., 2012) 
Tau exon 13-reverse 5’-TGGTCTGTCTTGGCTTTGGC-3’  (Rodriguez-
Martin et al., 
2005) 
Tau exon 9-forward 5’-CTGAAGCACCAGCCAGGAGG-3’  (Rodriguez-
Martin et al., 
2005) 
Tau35-HA-reverse 5’-TCAGGCGTAGTCGGGCAC-3’  (Krepulat et 
al., 2005) 
GAPDH-forward 5’-CCTGGCCAAGGTCATCCATGACAAC-3’  (Goetzl et al., 
1999) 
GAPDH-reverse 5’-TGTCATACCAGGAAATGAGCTTGAC-3’  (Goetzl et al., 
1999) 
*Forward Tau35 5’-CGTATGTGATGGACATGGAGATGGAGG-3’ genOway 
*Reverse Tau35 5’-GCCTCCCTCTTATTAAGGACGCTGAGG-3’ genOway 
*Forward HPRT 5’-TGTCCTTAGAAAACACATATCCAGGGTTTAGG-3’ genOway 
*Reverse HPRT 5’-CTGGCTTAAAGACAACATCTGGAGAAAAAA-3’ genOway 
 
*Indicates primers used for genotyping Tau35 and wild-type mice 
 
 
GAPDH = Glyceraldehyde 3-phosphate dehydrogenase; HA = Hemagglutinin; 
HPRT  = Hypoxanthine phosphoribosyltransferase   
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Supplementary Table 2: Antibodies for western blots and immunohistochemistry 
Antibody Epitope/ 
Immunogen 
Species/ 
Type 
WB IHC Source/ 
Reference 
Hemagglutinin 
(HA) 
HA tag 
(YPYDVPDYA) 
Mouse monoclonal  1/1,000 - Covance, HA.11 
HA HA tag Rabbit polyclonal - 1/1,000 Sigma-Aldrich, 
H6908 
Total tau C-terminal half of 
tau 
Rabbit polyclonal - 1/1,000 DAKO 
TP70 Tau C-terminus 
(amino acids 
428-441) 
Rabbit polyclonal 1/2,000 -  (Brion et al., 
1993) 
PHF1 Tau 
pSer396/pSer404 
Mouse monoclonal 1/1,000 1/500 P. Davies, 
(Greenberg et al., 
1992) 
TOC1 Tau oligomers Mouse monoclonal - 1/500 L.I. Binder, 
(Ward et al., 2013) 
MC1 Tau conformation Mouse monoclonal - 1/500 P. Davies, 
(Weaver et al., 
2000) 
AT8 Tau 
pSer202/pThr205/ 
pSer208 
Mouse monoclonal - 1/500 Thermo Scientific, 
(Mercken et al., 
1992) 
TP007 Tau N-terminus 
(amino acids 1-16) 
Rabbit polyclonal - 1/500  (Davis et al., 
1995) 
β-actin β-actin N-terminus Mouse monoclonal 1/10,000 - Abcam 
TG3 Tau 
pThr231 
Mouse monoclonal 1/1000 - P. Davies, 
(Dickson et al., 
1995) 
AT270 Tau 
pThr181 
Mouse monoclonal 1/2000 - Thermo Fisher 
Scientific, 
MN1050 
Tau1 Tau 
dephosSer199/ 
Ser202/Thr205 
Mouse monoclonal 1/200 - Merck Millipore, 
MAB3420 
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GFAP = Glial fibrillary acidic protein; GSK = Glycogen synthase kinase-3; 
HA = Hemagglutinin; IHC = Immunohistochemistry; WB = Western blot 
  
Glycogen 
synthase kinase-
3 (GSK3) 
GSK3α/β Rabbit polyclonal 1/1,000 - Enzo 
Phosphorylated 
GSK3 
pSer9/21 
GSK3α/β 
Mouse monoclonal 1/1,000 - Enzo 
Acetylated α-
tubulin  
Acetylated α-
tubulin 
Mouse monoclonal 
   [6-11B-1] 
1/1,000 - Abcam, 
(Piperno and 
Fuller, 1985) 
α-Tubulin α-Tubulin Rabbit polyclonal 1/10,000 - Abcam 
p62/SQSTM1 Human p62 
(14 amino acids 
near C-terminus) 
Mouse monoclonal 1/1,000 - Abcam, Ab91526 
Anti-LC3 Human, rat and 
mouse LC3A/B-I 
and LC3A/B-II 
Rabbit polyclonal 1/1,000 - Sigma-Aldrich, 
L7543 
Cathepsin D C-terminus of 
cathepsin D of 
human origin 
Goat polyclonal 1/2,000 - Santa Cruz 
Biotech, 
SC6486 
Synapsin-1 Bovine brain 
synapsin-1 
Rabbit polyclonal 1/1,000 - Merck Millipore, 
AB1543P 
Synaptophysin Human 
synaptophysin 
Mouse monoclonal 1/2,000 - Enzo, SP15 
Glial fibrillary 
acidic protein 
(GFAP) 
Mammalian 
GFAP 
Rabbit polyclonal 1/10,000 1/1,000 DAKO 
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Supplementary Table 3 
 
Semi-quantitative analysis of tau pathology in Tau35 mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunolabeling with tau antibodies PHF1, TOC1, MC1, AT8 and TP007 in the 
hippocampus (CA1 and CA3 regions) and cortex (Cx) of Tau35 mice. 
 
The extent of tau pathology was assessed in mice 2-16 months of age (n=3) using a semi-
quantitative scale of tau-positive inclusions: 
+++ Moderate inclusions 
++ Few inclusions 
+ No inclusions but increased background staining 
-  No tau immunoreactivity 
Antibody 2 months 8 months 14 months 16 months 
CA
1 
CA
3 
Cx CA
1 
CA
3 
Cx CA
1 
CA
3 
Cx CA
1 
CA
3 
Cx 
PHF1 ++ + + ++ ++ + +++ +++ ++ ++
+ 
++
+ 
++ 
TOC1 - - - + + + ++ ++ ++ ++
+ 
++
+ 
++ 
MC1 - - - + + + ++ ++ ++ ++
+ 
++
+ 
++ 
AT8 - - - + + + ++ ++ ++ ++
+ 
++
+ 
++ 
TP007 - - - + + + ++ ++ ++ ++
+ 
++
+ 
++ 
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Supplementary Figure Legends 
Supplementary Figure 1. Tau35 mice exhibit normal body weight, olfactory habituation 
and locomotor activity, but an early impairment in motor learning 
(A) Tau35 mice maintain equivalent weights to their wild-type (WT) littermates up to 18 
months of age. (B) Tau35 and WT mice (8 months) were assessed for the time spent sniffing 
each of three odours (water, banana and mouse urine). No impairment in olfactory senses or 
habituation learning was detected in Tau35 mice. (C) Locomotor activity was monitored in 
the open field test. Results are expressed as the time spent in the outer, middle or inner zone 
of the open field during an observation period of 10 min. No locomotor impairment was 
observed between Tau35 and WT mice at 8 months of age, indicating that there are no 
significant differences in anxiety between the two genotypes. Values shown are mean ± 
s.e.m., n=8 for each genotype. 
 
Supplementary Figure 2. No evidence of astrocytic activation in Tau35 mice 
(A) Western blot of hippocampal extracts from wild-type (WT) and Tau35 mice (14 months) 
probed with antibodies to glial fibrillary acidic protein (GFAP) show no change in 
expression, relative to actin. (B) Hippocampal sections from Tau35 and WT mice show no 
overt differences in GFAP expression or astrocytic morphology at 14 months of age. (C) 
Western blot of hippocampal extracts from wild-type (WT) and Tau35 mice (14 months) 
probed with antibodies to postsynaptic density protein (PSD95) show no change in 
expression, relative to tubulin. Scale bar=200µm. Values shown are mean ± s.e.m., n=6 for 
each genotype. 
 
Supplementary Figure 3. Tau mRNA expression is unchanged in phenylbutyrate-
treated and vehicle-treated Tau35 mice 
(A) Representative agarose gels show DY682-labelled RT-PCR products amplified using 
specific primers for Tau35 (tau exon 9 and the hemagglutinin tag, 558 base pairs [bp]) or 
endogenous mouse tau (tau exons 7 and 13, 612 bp), in phenylbutyrate (PBA)-treated and 
non-treated Tau35 mice. Primers amplifying glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were used for normalisation. Quantitation of the RT-PCR products shows no 
significant difference in expression of (B) Tau35, or (C) endogenous mouse tau, relative to 
GAPDH, between PBA-treated and vehicle-treated Tau35 mice. The results show mean ± 
s.e.m., n=3 for each genotype. 
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